Treatment of refractory juvenile idiopathic arthritis via pulse therapy using methylprednisolone and cyclophosphamide

Treatment of refractory juvenile idiopathic arthritis via pulse therapy using methylprednisolone and cyclophosphamide.

CONTEXT Patients with refractory juvenile idiopathic arthritis can benefit from aggressive therapy. CASE REPORT We followed the clinical course of 4 patients (2 male, 2 female) aged 9.1-17.8 years (mean of 14.5 years) with polyarticular onset of juvenile rheumatoid arthritis and one 16-year-old boy with juvenile spondyloarthropathy associated with inflammatory bowel disease. All the juvenile ...

'Pulse' methylprednisolone and cyclophosphamide therapy in idiopathic rapidly progressive glomerulonephritis.

The clinical report of a 31-year-old man who developed acute renal failure due to idiopathic rapidly progressive glomerulonephritis is presented. Intravenous pulse methylprednisolone therapy in combination with cyclophosphamide resulted in marked improvement in renal function. The literature dealing with pulse therapy is reviewed.

Treatment of refractory juvenile idiopathic arthritis.

Evaluation of clinical and laboratory symptoms of children with idiopathic arthritis treated with methylprednisolone pulse

Background: Juvenile idiopathic arthritis is the most common rheumatic disease in children, which includes a group of disorders that all have a common clinical manifestation of arthritis. The aim of this study was evaluation of the clinical and laboratory symptoms of children with idiopathic arthritis who treated with intravenous methylprednisolone pulse. Methods: This study is a descriptive c...

Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis.

Systemic-onset juvenile idiopathic arthritis (SOJIA), formerly called Still’s disease, is a subset of juvenile arthritis that describes patients with fever, rash, arthritis, serositis and visceromegaly. In up to 30% of cases the disease has a chronic course and management requires high doses of glucocorticoids, disease-modifying antirheumatic drugs (DMARD), tumour necrosis factor alpha (TNFa) i...